• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

MediWound

Tevosol taps Organ Recovery Systems vet Mills for CEO | Personnel Moves, June 17, 2019

June 17, 2019 By Brad Perriello

Tevosol said it named Organ Recovery Systems veteran Ron Mills to be its new CEO. “Ron knows our technology and our market,” co-founder & CSO Dr. Darren Freed said in prepared remarks. “He brings a wealth of relevant experience to our team and adds a spark of creativity to drive the next exciting stage of […]

Filed Under: Business/Financial News Tagged With: Amplifon, electroCore, Golden Meditech Holdings Ltd., MediWound, Obalon Therapeutics, Personnel Moves, Repro Med Systems, Sanara, sciton, Tevosol, Zimmer Biomet

MediWound lands $21m extension from BARDA to support NexoBrid

May 29, 2019 By Fink Densford

MediWound (NSDQ:MDWD) said today that the U.S. Biomedical Advanced Research and Development Authority (BARDA) upsized a contract with the company to provide a supplemental $21 million in funding. The newly acquired funding will be used to help launch the NexoBrid expanded access treatment protocol with the company’s NexoBrid product. The NexoBrid is a topically-administered product intended […]

Filed Under: Business/Financial News, Wall Street Beat, Wound Care Tagged With: MediWound

Vericel inks licensing deal for MediWound’s NexoBrid, posts Q1 earnings

May 8, 2019 By Fink Densford

Vericel (NSDQ:VCEL) said yesterday it inked an exclusive U.S. licensing and supply agreement with MediWound (NSDQ:MDWD) for its NexoBrid biological product, and reported first quarter earnings that missed expectations on Wall Street. The NexoBrid is a topically-administered product intended to enzymatically remove nonviable burn tissue in patients with deep partial and full-thickness thermal burns. The product has […]

Filed Under: Business/Financial News, MassDevice Earnings Roundup, Regenerative Medicine, Wall Street Beat, Wound Care Tagged With: MediWound, Vericel Corp

MediWound raises $25m

October 27, 2017 By Fink Densford

MediWound (NSDQ:MDWD) today announced a $25.2 million offering to support research and development of its EscharEx topical biological drug for debridement of chronic and other hard-to-heal wounds. In the offering, the Israel-based company floated approximately 5 million shares, including 637,664 shares through an underwriter’s option. Read the whole story on our sister site, Drug Delivery Business

Filed Under: Business/Financial News, Wound Care Tagged With: MediWound

MediWound touts Phase II study

January 31, 2017 By Sarah Faulkner

MediWound (NSDQ:MDWD) touted data from a phase II trial of its EscharEx topical biological drug for debridement of chronic and other hard-to-heal wounds. The data includes a follow-up period of 6 months from the last treatment to 3 months from wound closure. The randomized phase II trial enrolled 73 patients with a variety of chronic […]

Filed Under: Clinical Trials, Drug-Device Combinations, Pharmaceutical, Wound Care Tagged With: MediWound

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy